@article{oai:oist.repo.nii.ac.jp:00001699,
 author = {Vares, Guillaume and Jallet, Vincent and Matsumoto, Yoshitaka and Rentier, Cedric and Takayama, Kentaro and Sasaki, Toshio and Hayashi, Yoshio and Kumada, Hiroaki and Sugawara, Hirotaka},
 journal = {Nanomedicine: Nanotechnology, Biology and Medicine},
 month = {Apr},
 note = {Treatment resistance, relapse and metastasis remain critical issues in some challenging cancers, such as chondrosarcomas. Boron-neutron capture therapy (BNCT) is a targeted radiation therapy modality that relies on the ability of boron atoms to capture low energy neutrons, yielding high linear energy transfer alpha particles. We have developed an innovative boron-delivery system for BNCT, composed of multifunctional fluorescent mesoporous silica nanoparticles (B-MSNs), grafted with an activatable cell penetrating peptide (ACPP) for improved penetration in tumors and with gadolinium for magnetic resonance imaging (MRI) in vivo. Chondrosarcoma cells were exposed in vitro to an epithermal neutron beam after B-MSNs administration. BNCT beam exposure successfully induced DNA damage and cell death, including in radio-resistant ALDH+ cancer stem cells (CSCs), suggesting that BNCT using this system might be a suitable treatment modality for chondrosarcoma or other hard-to-treat cancers.},
 title = {Functionalized mesoporous silica nanoparticles for innovative boron-neutron capture therapy of resistant cancers},
 volume = {27},
 year = {2020}
}